新华鲜报丨打造“健康驿站”！9部门发文促药品零售行业高质量发展

Core Viewpoint - The joint opinion issued by nine departments aims to promote high-quality development in the pharmaceutical retail industry, transforming drugstores into "health stations" that provide professional services, health promotion, and emergency supply support [2][3]. Group 1: Policy Objectives - The document is the first dedicated policy for the pharmaceutical retail sector in China, focusing on enhancing the industry's service capabilities and meeting public health needs [2][4]. - The pharmaceutical retail market in China has expanded, with sales increasing from 2.41 trillion yuan in 2020 to an expected 2.95 trillion yuan in 2024 [4]. Group 2: Key Measures - The opinion outlines 18 measures to support drugstores in improving pharmaceutical service capabilities, optimizing purchasing experiences, participating in centralized drug procurement, and establishing payment security systems [3][4]. - Drug retail chains are allowed to establish their own pharmaceutical service platforms, enabling licensed pharmacists to provide remote prescription reviews and medication guidance [4]. Group 3: Quality Improvement - The opinion encourages the optimization of the drug business license application process and promotes the sale of innovative drugs and reference preparations through retail channels [5]. - Support for mergers and acquisitions among retail pharmacies and the integration of wholesale and retail operations is emphasized to enhance supply chain efficiency and promote fair competition [5]. Group 4: Accountability and Community Engagement - The document stresses the importance of emergency services in retail pharmacies, encouraging large chains to establish dynamic demand forecasting and low inventory warning systems [5][6]. - Retail pharmacies are encouraged to provide care measures for outdoor workers and collaborate with community committees and medical institutions to offer health care services [5][7]. Group 5: Industry Competition - The opinion promotes fair competition within the industry, advocating for collaboration between pharmaceutical manufacturers and large distribution companies to regulate drug pricing and maintain reasonable retail prices [6][7].